semaglutide and eye disease linked to risk of rare condition Novo Nordisk's Ozempic faces EU

Expansion of coverage under Medicare of GLP-1s to treat obesity under the BALANCE model is likely to increase utilization above current levels, as Medicare begins to meet the demand for obesity drugs among beneficiaries who have been unable to access or afford these medications to date

The effects of GLP-1s increase postprandial insulin secretion from pancreatic -cells, suppress glucagon secretion from -cells, slow gastric emptying, and reduce appetite (Gross)

Beside the insulinotropic effects, GLP-1 has been associated with numerous regulatory and protective effects

Devries MC, Phillips SM

Findings remained consistent across studies, reinforcing that semaglutide does not appear to negatively impact mental health in individuals without existing psychiatric conditions